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Abstract
Rationale: Targeted lung denervation (TLD) is a novel bron-
choscopic treatment for the disruption of parasympathetic 
innervation of the lungs. Objectives: To assess safety, feasi-
bility, and dosing of TLD in patients with moderate to severe 
COPD using a novel device design. Methods: Thirty patients 
with COPD (forced expiratory volume in 1 s 30–60%) were 
1: 1 randomized in a double-blinded fashion to receive TLD 
with either 29 or 32 W. Primary endpoint was the rate of TLD-
associated adverse airway effects that required treatment 
through 3 months. Assessments of lung function, quality of 
life, dyspnea, and exercise capacity were performed at base-
line and 1-year follow-up. An additional 16 patients were en-
rolled in an open-label confirmation phase study to confirm 
safety improvements after procedural enhancements fol-
lowing gastrointestinal adverse events during the random-
ized part of the trial. Results: Procedural success, defined as 
device success without an in-hospital serious adverse event, 
was 96.7% (29/30). The rate of TLD-associated adverse air-
way effects requiring intervention was 3/15 in the 32 W ver-
sus 1/15 in the 29 W group, p = 0.6. Five patients early in the 
randomized phase experienced serious gastric events. The 
study was stopped and procedural changes made that re-
duced both gastrointestinal and airway events in the subse-
quent phase of the randomized trial and follow-up confirma-
tion study. Improvements in lung function and quality of life 
were observed compared to baseline values for both doses 
but were not statistically different. Conclusions: The results 
demonstrate acceptable safety and feasibility of TLD in pa-
tients with COPD, with improvements in adverse event rates 
after procedural enhancements. © 2019 The Author(s)
Published by S. Karger AG, Basel
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
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Acetylcholine released from parasympathetic nerves 
in the lung is a key mediator of pathology in obstructive 
airways diseases through its induction of smooth muscle 
contraction, facilitation of reflex bronchoconstriction, 
incitement of mucus overproduction, and contribution 
to overall airway inflammation [1–4]. Changes in auto-
nomic activity and efferent parasympathetic overactivity 
have been identified as a source of dysfunction in ob-
structive airways disease [5–10].
Pharmacologic disruption of parasympathetic lung in-
nervation by inhaled anticholinergic therapies is the 
mainstay of chronic obstructive pulmonary disease 
(COPD) treatment. Permanent disruption or attenuation 
of parasympathetic nerves in patients with lung disease 
has the potential to provide long-lasting anticholinergic 
effects and consistent relief of obstructive lung disease 
symptoms/exacerbations. Targeted lung denervation 
(TLD) is a novel bronchoscopic therapy designed to at-
tenuate the parasympathetic pulmonary branches of the 
vagus nerve that run along the outside of the mainstem 
bronchi, thereby disrupting the innervation to the entire 
lung. Early feasibility studies demonstrated that TLD 
could be performed safely providing a clinical benefit for 
COPD patients [11–13].
Major enhancements were made to the TLD system 
and device (online suppl. Fig. S1; for all online suppl. ma-
terial, see www.karger.com/doi/10.1159/000500463) af-
ter the initial feasibility studies [11, 13]. These changes 
include compatibility of the catheter with flexible bron-
choscopy and a larger electrode to decrease procedure 
time. The AIRFLOW-1 trial is the first study to evaluate 
the safety of this second-generation version of the device 




The AIRFLOW-1 study was initiated to assess airway safety 
and to evaluate TLD energy dose by randomizing between 2 se-
lected doses (29 vs. 32 W). Thirty subjects were randomized 1: 1, in 
a double-blind, multi-center study conducted at 10 Western Euro-
pean sites between August 4, 2014, and July 16, 2015. Major entry 
criteria included COPD defined as the ratio of post-bronchodila-
tor forced expiratory volume in 1 s (FEV1) to forced vital capacity 
(FVC) of ≤0.70 and post-bronchodilator FEV1 of 30–60% of pre-
dicted normal values, age ≥40 and ≤75 years, persistent symptoms 
indicated by either Modified Medical Research Council (mMRC) 
grade ≥2 and/or COPD assessment test (CAT) score ≥10, and re-
versibility to anticholinergic medications as demonstrated by a 
positive relative change in FEV1 and/or FVC of > 12% and > 200 mL 
following inhalation of 80 μg ipratropium bromide. A complete 
listing of all study inclusion and exclusion criteria can be found in 
online supplement Table S1.
Procedures
Following informed consent and screening, subjects had base-
line testing after a washout period from their inhaled bronchodila-
tors consisting of ≥7 days for long-acting muscarinic antagonists, 
72 h for ultra-long-acting beta agonist, 24 h for long-acting beta 
agonist, and 12 h for short-acting beta agonist. Current American 
Thoracic Society (ATS)/European Respiratory Society (ERS) 
guidelines were followed for pulmonary function testing [14]. The 
St. George’s Respiratory Questionnaire (SGRQ-C) [15], the CAT 
[16], and the EuroQol five-dimension five-level scale utility index 
and visual analogue scale [17] were used to assess quality of life and 
health status. Baseline and Transition Dyspnea Index and mMRC 
Scale [18] were used to assess dyspnea. Cycle ergometry training 
was implemented during washout using ATS/ACCP guidelines 
[19] to first establish a baseline maximum work rate (Wmax) off 
drugs and subsequently as an endurance test conducted at a con-
stant work rate of 75% of the Wmax [20]. Baseline chest CT-scans 
were obtained and analyzed by an independent core lab (VIDA 
Diagnostics, Coralville, IA, USA) to assess bronchial anatomy and 
the level of emphysema (using automated emphysema quantifica-
tion at a threshold of –950 HU), to rule out other pulmonary ab-
normalities.
Follow-up bronchoscopy was performed on all patients at 3 
months to evaluate airway wall effects. At 12 months, all baseline 
testing was repeated in all available patients for comparison to pre-
treatment baselines under the same conditions after bronchodila-
tor washout. Safety events were monitored continuously during 
the follow-up period.
Randomization and TLD Treatment
All patients underwent TLD to both lungs in a single procedure 
under general anesthesia. The choice of airway access (rigid bron-
choscopy, endotracheal tube, laryngeal mask) and mode of ventila-
tion was left at the discretion of the operator.
Chest CT-scans obtained at baseline and bronchoscopic in-
spection at the time of the procedure were used to assess airway 
compatibility with the dual cooled radiofrequency (RF) catheter 
prior to randomization. After confirmation of airway compatibil-
ity, randomization was performed using tamper-resistant sealed 
envelopes that contained letter codes that were entered into the 
console to deliver the appropriate RF power level for treatment. 
This allowed for a triple-blind study design to be conducted with 
the treating physician, subject, and follow-up physician all un-
aware of the exact RF energy level provided. After randomization, 
the treatment catheter was advanced through the bronchoscope, 
and circumferential treatment was achieved by activating the elec-
trode in up to 4 positions per bronchi (online suppl. Fig. S1). Bron-
choscopic and fluoroscopic visualization was used to guide elec-
trode placement before and during energy delivery. All patients 
were prescribed 25–30 mg prednisone and 500 mg of azithromycin 
daily for 1 day before and 2 days after the procedure. All subjects 
remained on standard dosing of tiotropium bromide for a mini-
mum of 90 days. No additional post procedure medication was 
required. Investigators could treat respiratory symptoms per stan-
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dard of care and published guidelines. Time to discharge was left 
to institutional practice.
Open-Label Confirmation Study Following Procedural 
Enhancements
After treatment of the first 13 subjects in the randomized dose 
evaluation phase, reports of gastric adverse events led to a suspen-
sion of treatments and a detailed investigation of all pertinent 
events, procedure videos, fluoroscopic images, and records from 
the TLD system. The investigation suggested that these events 
were related to inadvertent injury to esophageal branches of the 
vagus nerve during treatment. Following approval by the indepen-
dent data monitoring committee and protocol steering committee, 
protocol, procedural, and training enhancements were imple-
mented to ensure optimal placement, visualization, and confirma-
tion of the electrode position relative to the esophagus prior to 
activation to mitigate against further gastric events. The new pro-
cedure version included fluoroscopic visualization and active mea-
surement of the distance between the electrode and the outer wall 
of the esophagus, by use of a commercially available esophageal 
balloon (CRETM, Boston Scientific or Hercules® 3, Cook Medical) 
filled to low pressure with a contrast agent and saline, to assist in 
avoiding the thermally sensitive vagus nerve (online suppl. Table 
S2). To further mitigate gastrointestinal side effects, low power (26 
W) was used for treatment positions close to the main carina. The 
treatment algorithm used per protocol is provided in online suppl. 
Table S2.
After appropriate protocol amendment and ethics approvals, 
17 patients continued enrollment in the randomization dose study 
and 16 additional patients were enrolled and treated in an open-
label confirmation study between November 2, 2015, and June 14, 
2016 (after the dosing phase was completed) to confirm the impact 
of protocol, procedural, and training enhancements on gastric 
safety. Patient inclusion and exclusion criteria as well as baseline 
and follow-up testing were identical to the randomized dose eval-
uation phase with the additional exclusion of patients with a his-
tory of prior abdominal surgical procedures, a baseline gastropa-
resis cardinal symptom index score ≥18, as part of the patient as-
sessment of gastrointestinal disorders symptom severity index [21] 
prior to treatment, or recent (< 3 months ago) narcotic use.
Study Endpoints
The primary safety endpoint for the randomized dose evalua-
tion phase was the rate of TLD-associated adverse airway effects 
that required a therapeutic intervention (defined as the adminis-
tration of antibiotics, conduction of another diagnostic test to as-
sess the treatment area, or an endoscopic procedure or surgery to 
treat findings) through 3 months posttreatment.
Secondary endpoints included procedural success (defined as 
the ability to insert and place the catheter to its intended locations 
and intact removal without the report of an in-hospital serious ad-
verse event [SAE]), overall adverse events, and change from base-
line to 1-year for pulmonary function tests, health-related quality 
of life, dyspnea, and exercise capacity assessments. At the 1-year 
follow-up visit, patients were tested following a washout period 
identical to baseline testing. The primary safety endpoint for the 
open-label confirmation phase was the rate and frequency of ad-
verse events through 1-month posttreatment compared to the ran-
domized dose evaluation phase. Secondary endpoints were identi-
cal to the randomized dose evaluation phase.
Statistical Methods
As no primary statistical hypothesis was proposed, the study 
sample size was not based on formal statistical power calculations. 
The sample size of 30 (15 subjects per dose) in the randomized 
dosing group would not allow for the detection of differences be-
tween groups in pulmonary function testing. A sample size of 15 
in the open-label confirmation study was selected to appropriately 
compare rates and frequency of adverse events to the optimal dose 
group selected from the randomized dosing phase. All p values 
were presented for informational purposes only. According to the 
prespecified analysis plan, continuous data were summarized us-
ing means and SD. Categorical data were tabulated, with counts 
and percentages. All monitored and available data were summa-
rized, with no imputation for missing data. The final analyses were 
conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC, 
USA) by an independent statistical group (NAMSA, Minneapolis, 
MN, USA).
Safety Monitoring
Each patient signed a written consent form. Study approval was 
obtained by local Ethics Committees and in accordance with the 
Declaration of Helsinki (1996), Good Clinical Practice guidelines, 
and any local requirements. A protocol steering committee and an 
independent data monitoring committee oversaw protocol man-
agement and overall safety for the study. An independent clinical 
events committee adjudicated all reported SAEs and any non-se-
rious event deemed relevant by the study safety officer, using orig-
inal and monitored source documentation from the site.
This trial is registered with ClinicalTrials.gov, number 
NCT02058459.
Results
Randomized, Dose Evaluation Study
Patients and Procedure
Baseline characteristics are shown in Table 1. Patients 
included had evidence of moderate–severe airflow ob-
struction, and other characteristics were well balanced 
between the 29 W (n = 15) and 32 W (n = 15) treatment 
groups.
Procedural details are shown in Table 1. Acute proce-
dure success was 96.7% (29/30) with 1 report of aphonia 
following TLD due to the introduction of a rigid broncho-
scope, which did not require hospitalization but required 
speech therapy and a 1-day lipofilling of the vocal cord for 
treatment. The patient had a normal vocal cord exam at 
6-month follow-up. In total, 90% (27/30) of patients were 
discharged within 24 h after the procedure. One-year fol-
low-up data were available for 80% (24/30) of the patients 
(Fig. 1).
Safety Outcomes
Immediate post procedure airway inspection was per-
formed in all patients, and typical findings consisted of 
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whitish mucosal blanching at the site of treatment. Fol-
low-up bronchoscopy at 3 months was performed on 14 
patients in the 32 W group and 13 patients in the 29 W 
group. Typical findings consisted of normal airway. Fig-
ure 2 shows an example of typical early airway findings 
posttreatment and during 3-month follow-up airway in-
spection.
Four subjects, 1 in the 29 W group (6.6%) and 3 in the 
32 W group (20%) met the primary safety endpoint. In 
the 29 W group, 1 subject was found to have a small (∼1 
mm) nodule at a treatment site in the right main stem 
during the 3-month airway inspection and prompted the 
physician to repeat bronchoscopy at 6 months at which 
time the nodule had resolved. In the 32 W group, 1 patient 
was found to have a small (∼1 mm) nodule at a treatment 
site, which resolved by the 6-month follow-up without 
intervention. A second patient was prophylactically given 
steroids and antibiotics in response to a larger area of 
whitish mucosal blanching immediately posttreatment 
with normal healing observed at the 3-month airway in-
spection. The third patient developed pneumonia that 
was poorly responsive to antibiotics, which led to inten-
sive care admission with bronchoscopy and the discovery 
of a deep ulceration at the medial side of the right main 
stem bronchus with a mucosal fistula through the thin 
tissue of the carina and a partial occlusion of the right up-
per lobe bronchus. Repeat assessments showed progres-
sive local healing with a complete clinical recovery of the 
patient.
Table 1. Patient baseline characteristics and procedure characteristics
Dosing group Confirmation group
29 W group (n = 15) 32 W group (n = 15) 32 W (n = 16)
Age, years 61 (8) 64 (6) 63 (6)
Male, n (%) 9 (60) 4 (27) 6 (38)
Ethnic origin, white, n (%) 14 (93) 15 (100) 16 (100)
Smoking pack-years 43 (23) 47 (28) 41 (11)
BMI 25 (3) 25 (3) 26 (3)
FEV1 post bronchodilator, L 1.11 (0.3) 1.09 (0.2) 0.97 (0.2)
FEV1/FVC post bronchodilator, L 35 (9) 37 (8) 33 (5)
Reversibility peak change in FEV1, % 19 (7) 20 (10) 22 (11)
FEV1 at washout, L 0.88 (0.3) 0.86 (0.2) 0.81 (0.2)
FEV1 at washout, % 31 (5) 36 (10) 32 (6)
FVC at washout, L 2.73 (0.8) 2.52 (0.5) 2.62 (0.7)
FVC at washout, % 77 (12) 84 (11) 85 (17)
Cycle endurance, min 7.01 (4) 9.42 (9) 8.55 (9)
Emphysema, %* 31 27 32
Airway access, n (%)
Endotracheal tube 11 (73) 9 (60) 12 (75)
Rigid bronchoscope 4 (26) 6 (40) 3 (19)
Laryngeal mask 0 (0) 0 (0) 1 (6)
Left lung treatment, n (%)
≥4 activations 14 (93) 15 (100) 15 (94)
<4 activations 1 (7) 0 (0) 1 (6)
Right lung treatment, n (%)
≥4 activations 13 (87) 12 (80) 9 (56)
<4 activations 2 (13) 3 (20) 7 (45)
Average catheters used 1.3±0.5 1.5±1.1 1.44±0.5
Total procedure time, min 72±22 67±20 67±14
Total fluoroscopy time, min 5.0±3.5 3.9±4.0 4.4±1.5
Discharge within 24 h, n (%) 14 (93) 13 (87) 15 (94)
Data are mean (SD) unless stated otherwise.* Core lab measurements using –950 HU (VIDA Diagnostics, Coralville, IA, USA).
No statistical difference between 32 and 29 W (p > 0.05) for any parameter.
BMI, body mass index; FEV1, forced expiratory volute in 1 s. FVC, forced vital capacity. 
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A complete listing of all SAEs reported out to 1 year is 
provided in Table 2. There was 1 death due to aortic dis-
section and rupture 6 days posttreatment. The patient 
had a history of dissection and stenting 7 years prior to 
the current intervention, which was assessed by autopsy 
to be unrelated to TLD. Another patient experienced a 
non-ST-elevation myocardial infarction at 68 days post-
treatment that was not related to the procedure. Overall 
SAE rates were numerically higher in the 29 W group 
than in the 32 W group with impaired gastric emptying 
in 5 patients (16.6% of treated population) being the most 
commonly reported. Four of these 5 patients treated un-
Main exclusions:
– non-reversible (n = 7)
– FEV1 high/low (n = 6)
– withdrew consent (n = 5)
– BMI high/low (n = 4)







for screening (n = 75)
Treated (n = 30)
(procedural modifications
implemented after n = 13)
Allocation
Lost to follow-up (n = 1)
– subject withdrew
Missed 1-year visit (n = 1)
Lost to follow-up (n = 2)
– death
– subject withdrew
Missed 1-year visit (n = 2)
Follow-up
n = 13 n = 11
Analysis
Main exclusions:
– FEV1 high/low (n = 8)
– recent exacerbation (n = 6)
– non-reversible (n = 3)
– no pulmonary rehab (n = 3)
– CT scan finding (n = 3)
Open label confirmation
registry consented
for screening (n = 40)
Treated (n = 16)
(32 W)
Lost to follow-up (n = 1)
– subject withdrew
Missed 1-year visit (n = 1)
n = 14
0
Fig. 1. Study flow charts for randomized dose evaluation and open-label confirmation patients.
Baseline: right bronchus prior to treatment Acute effect after treatment 3-month follow-up
Fig. 2. Example of typical airway response to TLD over time. Typical airway findings following the TLD proce-
dure. The 3 images from left to right depict the right main bronchus of a treated patient immediately prior to 















der the original procedure design continued to experi-
ence symptoms of impaired gastric emptying 1-year post 
procedure. Of these 4 patients, 3 experienced ameliora-
tion of symptoms with treatment before their 1-year fol-
low-up and complete resolution of impaired gastric emp-
tying during follow-up beyond 1 year. A reduction in 
both occurrence and severity of gastric events was noted 
in the remaining subjects treated after procedural en-
hancements, both in the randomized dose evaluation 
phase and in the open-label study (Table 1 and online 
suppl. Table S4). A complete list of all adverse events is 
displayed in online supplemental Table S3.
Efficacy Outcomes
At 1 year during the bronchodilator washout study vis-
it, improvements in FEV1 of 94.2 ± 228 mL (p = 0.18), 
FVC 212 ± 497 mL (p = 0.17), SGRQ-C –7.5 ± 10.3 (p = 
0.036), and CAT –2.9 ± 6.1 (p = 0.14) were observed in 
the 32 W group compared to baseline. The 29 W group 
had changes in FEV1 of 57 ± 82 mL (p = 0.0272), FVC 238 
± 316 mL (p = 0.0188), SGRQ-C –1.9 ± 12.5 (p = 0.6166), 
and CAT 0.3 ± 7.8 (p = 0.8898) compared to their base-
line. The difference between groups did not reach statisti-
cal significance (Table 3, Fig. 3).
An exploratory post hoc bivariate analysis was per-
formed on 1-year FEV1 or SGRQ-C outcomes and is list-
ed in online supplemental Table S5.
Open-Label Confirmation Study
All patients in the open-label study received TLD with 
32 W. Patients in this study had similar baseline charac-
teristics and procedural details (Table 1) to those in the 
randomized dosing phase group, with the exception of 
more frequent “incomplete” circumferential TLD treat-
ment of the right lung (45% with < 4 activations in the 
right lung) in the open-label study. This was due to the 
Table 2. Primary endpoint and 12-month SAEs
Dosing group Confirmation group
29 W (n = 15) 32 W (n = 15) 32 W (n = 16)
Primary endpoint# (% of patients) 1 (6.6) 3 (20) 0 (0)
Total, SAEs (patients) 16 (9) 14 (5) 9 (5)
Pulmonary, events (patients) 5 (3) 6 (3) 5 (4)
COPD exacerbation 3 3 2
Pneumonia 1 1 1
Bronchitis – – 1
Cough – – 1
Aphonia 1 – –
Bronchial fistula – 1 –
Non-small-cell lung cancer – 1 –
Gastrointestinal, events (patients) 7 (6) 4 (3) 0 (0)
Impaired gastric emptying 3 2 –
Epigastric discomfort – 1 –
Nausea 1 – –
Duodenal ulcer hemorrhage 1 – –
Cholecystitis acute – 1 –
Colitis 1 – –
Diverticulitis 1 – –
Cardiac, events (patients) 0 (0) 2 (2) 0 (0)
Aortic dissection, death – 1 –
Acute myocardial infarction – 1 –
Other, events (patients)* 4 (3) 2 (2) 3 (2)
# Percentage of patients with bronchoscopic airway effects that required a therapeutic intervention through 
3-month posttreatment.*  Other events included: 29 W Dosing Group: urine retention, iron deficiency anemia, depression, and 
bursitis. 32 W Dosing: non-cardiac chest pain, arthritis; 32 W Confirmation Group: non-cardiac chest pain, 
tendonitis, and hypoglycemia.
SAE, serious adverse event.
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proximity of the RF electrode to the esophageal balloon, 
compared with the randomized dosing study (16% with 
< 4 activations in the right lung; Table 1). Acute procedure 
success was 94% (15/16) with the RF catheter being un-
able to be re-inserted after removal for cleaning in 1 pa-
tient. One-year follow-up data were available for 88% 
(14/16) of patients (Fig. 1). When considering SAEs ad-
judicated as related to TLD, only 1 out of 16 patients (6%) 
had an SAE in the 1-month posttreatment period of the 
confirmation study (Fig. 4). Overall SAE rates during the 
course of the study are listed in Table 2. Secondary end-
points are shown in Table 3. Clinically meaningful im-
provements were observed for the SGRQ-C (57% of pa-
tients with ≥4 point drop) and CAT (79% of patients with 
≥2 point drop) score at 1 year.
Discussion
The present study demonstrated overall safety and fea-
sibility of TLD in patients with moderate to severe COPD. 
Reports of gastric adverse events during the randomized 
Table 3. Changes at 1-year from baseline washout off bronchodilators






(32 vs. 29 W)
32 W
(n = 16)
FEV1, mL 94±228 57±82 0.6050 34±174
FVC, mL 212±497 238±316 0.8761 208±528
TLC, L 0.04±0.21 0.01±0.30 0.8173 0.19±0.7
RV, L –0.12±0.52 –0.23±0.55 0.6311 –0.01±1.0
IC, L –0.04±0.28 –0.07±0.44 0.8374 0.06±0.3
SGRQ-C –7.5±10 –1.9±12 0.2534 –6.1±21
CAT –2.9±6.1 0.3±7.8 0.2800 –6.2±9.6
EQ-5D 0.1±0.2 0.0±0.2 0.6930 0.1±0.2
EQ-5D VAS 9.1±21 3.2±14 0.4229 0±22
mMRC 0.1±0.9 0.0±0.7 0.7900 –0.2±0.7
TDI 0.5±2.7 –0.7±4.3 0.4516 1.3±3.8
Exercise endurance*, min –2.7±8 –0.3±4.7 0.7969 –2.1±9.3* Performed at 75% of Wmax.
FEV1, forced expiratory volume in 1-s; FVC, forced vital capacity; TLC, total lung capacity; RV, residual 
volume; IC, inspiratory capacity; SGRQ-C, COPD specific St. Georges Respiratory questionnaire; CAT, COPD 
Assessment Test; EQ-5D, EuroQol Health Assessment – 5 dimensions; mMRC, Modified Medical Research 






























29 W 32 W
SGRQ-C
Fig. 3. Changes in secondary efficacy out-
comes from baseline in the randomized 
dose evaluation study. The change in (a) 
FEV1 response and (b) SGRQ-C from 
washout baseline at 1 year in the 29 and 32 
W dosing groups. FEV1, forced expiratory 
volume in 1 s; TLD, targeted lung denerva-




dosing study prompted procedural enhancements, with a 
subsequent reduction in treatment-related gastric side ef-
fects confirmed in an open-label phase.
TLD is a novel bronchoscopic approach that disrupts 
the parasympathetic innervation of the lungs, while min-
imizing damage to tissues of the main bronchi through 
the use of a dual cooling method [11, 13]. Post procedure, 
the distal segments of the targeted nerve fibers are discon-
nected from their proximal segments due to thermal in-
jury [22–26]. They undergo the process of Wallerian de-
generation that degrades these distal fibers all the way out 
to their peripheral endings, with persistent cessation of 
acetylcholine release [27, 28].
Early in the randomized dosing phase of the study, 
gastrointestinal SAEs were observed. The symptoms were 
similar to side effects reported in patients who undergo 
catheter ablation of atrial fibrillation. Ablation in the atri-
um is in close proximity to the esophagus, on the outside 
of which runs the esophageal–vagal plexus that goes on 
to innervate the stomach [29–31]. In fact, gastrointestinal 
complications such as gastroparesis, esophageal thermal 
lesions, esophageal ulcers, and other signs of symptom-
atic periesophageal vagal plexus injury were reported in 
as high as 40% of patients treated for atrial fibrillation 
[32]. In response to reports from patients with impaired 
gastric motility in the current study, the study was halted 
and procedural modifications were implemented to ad-
dress these events. The procedural change utilized an 
esophageal balloon to allow the physician to visualize the 
esophagus and make a fluoroscopic assessment of the dis-
tance between the RF electrode and the esophagus. A 
treatment plan was developed based on extensive preclin-
ical testing that allowed for a reduction in energy levels 
for activations at sites close to the esophagus. The proto-
col, procedural, and training modifications reduced the 
incidence of SAEs that could be directly attributed to the 
procedure. The rate of SAEs dropped by more than half 
in the remaining patients treated in the randomized dos-
ing phase, and gastrointestinal SAEs were eliminated in 
the confirmation phase.
The higher energy dose was selected for the open-label 
study due to a trend toward more favorable clinical out-
comes, that is, improvements in lung function and qual-
ity of life data, in the absence of differences in the adverse 
events profile between the 2 energy groups in the blinded 
randomized phase of the study. Noteworthy, there were 
no changes in medication during follow-up.
In contrast to the first-generation device of TLD [11, 
13], which required rigid bronchoscopy, the technology 
used in the current study allowed placement of the RF 
catheter through the working channel of a flexible bron-
choscope. This second-generation device incorporated a 
longer electrode, which reduced the number of required 
RF activations by 50% and shortened the procedure time. 
Compared to the first-in man reports of TLD [11, 13], the 
current study evaluated 2 slightly higher dose power lev-
els that were based on extensive preclinical work [22–26] 
and were intended to maximize efficacy while maintain-
ing safety.
Consequently, the primary outcome in the current safe-
ty study was the rate of acute airway wall effects. These ef-
fects were observed in 15% of treated patients, with full res-
olution of all events at follow-up visits. In comparison to 
other bronchoscopic treatments for COPD, TLD appears 
to have a low rate of respiratory-related adverse events in 
the perioperative period. In contrast, patients treated with 
endobronchial coils experience rates of pneumonia causing 
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■ SAE 0–3 months
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Fig. 4. SAE adjudicated as directly related 
to TLD. The figure depicts the SAEs that 
were adjudicated as directly related to the 
TLD procedure broken out by power, study 
group, and time period post procedure. 
The patients treated at 29 W during the 
randomized dosing phase of the study ex-
perienced the highest rate of TLD-related 
SAEs in the 40 days following the proce-
dure. The procedural, protocol, and train-
ing changes evaluated in the confirmation 
phase resulted in the lower post procedure 
TLD-related SAEs. SAE, serious adverse 
event.
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rates reported as high as 30% [34, 35] for valve treatment in 
patients with emphysematous phenotype of COPD [36]. 
TLD appears to provide a favorable clinical benefit with 
consistent respiratory safety, according to the current re-
port and the previous first-in human studies.
Following TLD in the dosing phase, 1 patient exhibited 
a deep ulceration at the medial side of the right main stem 
bronchus with a mucosal fistula through the thin tissue of 
the carina and a partial occlusion of the right upper lobe 
bronchus. Analysis of videos from clinical procedures 
and bench top studies of ablations with the device (un-
published data) indicate that the observed ulceration and 
fistula were likely caused by poor balloon contact and 
treatment along the medial wall of the right main stem. 
The cooling fluid circulated underneath the electrode and 
through the balloon during energy delivery cools the sur-
face of the airway wall. When the balloon fails to make 
appropriate contact with the airway wall, heat from the 
energy delivery builds up at the surface of the airway 
which can cause ulceration. Additionally, the medial wall 
of the right main bronchi has been found to be susceptible 
to overheating due to airway anatomy. The right medial 
treatment location is near the main carina, which is a 
thinner tissue layer than that of other treatment locations. 
Heat likely accumulates in thinner tissue due to a decrease 
in heat loss from tissue perfusion. The results of both of 
these observations were changes to the implementation 
of the procedure that ensure the contact of the balloon to 
the airway wall and lowering power in medial location of 
the right main stem bronchi regardless of distance from 
the esophagus. The absence of significant ulcerations or 
fistula in the conformation portion of the study is indica-
tive of the impact of the procedural changes.
Improvements observed in quality of life and COPD 
symptom scores appear to indicate a dose–response rela-
tionship of TLD, with patients treated at higher energy 
levels (32 W) experiencing clinically meaningful benefits 
using common threshold for the SGRQ-C (–4 points) [16, 
37]. However, we have to acknowledge that the sample 
size of the current study was powered to formally assess 
neither noninferiority of safety outcomes nor superiority 
of efficacy outcomes between the individual dosing 
groups. This may also potentially explain the absence of 
symptomatic improvements using other patient-report-
ed tests, such as the mMRC. In this context, it needs to be 
acknowledged that different symptom scores may pres-
ent different aspects of the disease, with the mMRC not 
equally representing the full spectrum of symptomatic 
burden compared with other self-reported question-
naires [38].
Another potential shortcoming of our study is the ab-
sence of a control group. Nevertheless, the blinded dose 
response observed in the current study suggests an inter-
vention effect. A randomized, sham-controlled study 
(AIRFLOW-2 NCT02058459) is currently under way to 
understand the impact of this potential limitation.
In summary, the current study evaluated a novel sec-
ond-generation TLD device. During the early phase of 
this study, procedural changes were implemented that 
markedly improved the safety profile of the procedure. 
Ultimately, the study demonstrated safety and feasibility 
of TLD using a novel device design in patients with mod-
erate-to-severe COPD.
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